It may increase sympathetic activity—the part of the nervous system that raises heart rate and blood pressure. For people with certain heart conditions, this extra workload may increase the risk of complications. It is possible that some people may not connect a fast heart rate to their testosterone use and may not report it. Certain people may be more at risk for developing a fast heart rate while on TRT. Food and Drug Administration (FDA), fast heart rate has been seen in a small number of people taking testosterone. More frequent side effects include acne, oily skin, increased red blood cells (polycythemia), and mood changes. Testosterone replacement therapy (TRT) is used to help men with low testosterone levels feel better. This type of study design generally entails measurement of a single, or possibly two, serum T levels in participants, whose health trajectories are then followed over the ensuing years. Similar to these cross-sectional analyses, longitudinal data have shown mixed findings, although most studies have not demonstrated a relationship between circulating T levels and incident CVD. However, while these types of analyses attempt to control for covariates, they do not allow clear discernment as to whether T levels are directly related to CVD risk or, alternatively, serve as a marker of ill health overall. While meta-analyses of such trials suggest that TRT does not increase CVD risk, a recent randomized trial suggested that TRT might increase risk in certain clinical populations . Cardiovascular risk increases in men with age in tandem with declining endogenous testosterone (T) production. Since these advisories were issued, additional observational studies have been conducted to assess the impact of ADT on cardiovascular outcomes. In the same year, however, D'Amico et al.47 pooled data from 3 RCTs examining short-term androgen suppression therapy and found that older men who received androgen suppression therapy had shorter times to fatal myocardial infarctions than those who did not receive therapy. Ruige et al.21 reported a weak pooled protective effect of total testosterone on CVD in healthy men. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; QTc interval, heart-rate–corrected QT interval; RBC, red blood cell. Thirty training sessions were programmed for participants to complete, with an adherence rate of 80% required for data inclusion. All participants were currently regularly exercising, but not pursuing any specific health or fitness goal (e.g., weight loss or competition preparation) for at least six months prior to study commencement. Previous studies demonstrate that HRV is sensitive to individual variation in adaptation, fatigue, and overload during exercise training programs (13, 14, 42). HRV is estimated by measuring the time intervals between successive heartbeats, where an increase or decrease in these intervals reflects cardiac parasympathetic activity (32). A promising non-invasive tool, heart rate variability (HRV), monitors internal TL and adaptation via the ANS and provides valuable insight into fatigue monitoring (1, 32, 42). Finally, multiple consensus statements from a variety of societies have consistently stated that bioidentical hormones should not be used, and that only FDA-approved preparations should be used. They also reference the National Academies of Sciences, Engineering, and Medicine’s review of the use of compounded bioidentical hormone therapy (cBHT). It is meaningless to compare cohort groups in terms of side effects because only 4.5% of the patients in the FHT group received testosterone, versus 99% of the women in the PHT group. This commentary was written by physicians who are not experts in the field of testosterone therapy in women. Another more recent long-term cohort study, entitled the Testosterone Therapy and Breast Cancer Incidence Study, followed over 2300 pre- and post-menopausal women receiving testosterone with and without estrogen. The failure to administer oral progesterone in women with a uterus on estrogen replacement therapy remains a clinical mistake that leads to hyperplasia and, potentially, adenocarcinoma of the endometrium. This has clinical implications, for example while considering ADT, which is the cornerstone of the treatment of prostate cancer. While the authors have found no difference in the expression levels of calcium homeostasis proteins, they showed a decreased Cx43 expression, which correlated with slowed conduction velocity in female mice, but not in males. Furthermore, as previously mentioned, testosterone may augment outward repolarizing currents (such as Ikr and Iks), and thus, lead to loss of the AP dome, explaining the male predominance of the Brugada Syndrome. Furthermore, the same group has also studied hiPSCs from men and treated them either with ADTs and dihydrotestosterone, reporting that while the ADTs indeed prolonged the QT interval, this was acutely reversed upon dihydrotestosterone administration (60). This condition defines prolonged rate-corrected QT intervals (QTc) in patients who are at risk for ventricular tachyarrhythmias (typically TdP) and SCD (36). The lack of estrogen together with an excess in catecholamines may not only underlie the pathophysiology of the disease itself, but also the risk of arrhythmic complications. This is in contrast with the mechanisms of arrhythmogenesis in patients with outflow tract ventricular tachyarrhythmias in the absence of structural heart disease. Hormones regulate heart rate variability by directly acting on the autonomic nervous system, with cortisol and thyroid hormones having the strongest documented effects on HRV metrics. How cortisol, testosterone, and other hormones interact with heart rate variability Dr. Davis and her consensus panel agreed that HSDD is a clinical diagnosis and that, therefore, serum testosterone levels should not be used to make a diagnosis . The trial demonstrated adverse cardiovascular disease events and an increased risk of breast cancer, deep vein thrombosis, and Alzheimer’s disease in female patients in the combined estrogen plus progestin (E + P) arm, but not in the CEE-only arm. Perhaps it is time for the FDA to consider approving products that would benefit testosterone-deficient women. The safety of testosterone use in women has been evaluated for the past 80 years. This has resulted in millions of women suffering in silence with very common symptoms of perimenopause and menopause that could easily be addressed with the use of testosterone. According to Panay and Fenton , young women’s ovaries produce approximately three to four times more testosterone than estrogen daily. It therefore stands to reason that an imbalance in androgen biosynthesis or metabolism in women may have undesirable effects on any or all of these domains. A double-blind randomized trial demonstrated that androgens affect sexual desire, bone density, muscle mass and strength, adipose tissue distribution, mood, energy, and psychological well-being . Notwithstanding this, controversy exists concerning the existence of androgen-deficiency states and their clinical diagnosis and management. In England and Australia, testosterone has been licensed for use in women for more than 60 years.
.jpg)
